Medically ill patients present a high risk for venous thromboembolism (VTE). Two medications (rivaroxaban, enoxaparin) are currently approved as prophylactic treatments against VTE. This study examined total care costs associated with each treatment. Analyses was performed by constructing decision-tree models incorporating clinical outcome probabilities and costs of healthcare resource consumption. Monte Carlo analyses using 10,000 subject simulations with sensitivity analyses was performed. The expected value (EV), or lowest cost strategy, per subject favored enoxaparin over rivaroxaban ($1,271 versus $1,650; 22.3% difference). These results are important in clinical and formulary decisions.
LINK TO PRESENTATION VIDEO
